Seven Eight Capital LP Sells 828 Shares of DexCom, Inc. (NASDAQ:DXCM)

Seven Eight Capital LP lowered its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 14.0% during the first quarter, Holdings Channel.com reports. The firm owned 5,102 shares of the medical device company’s stock after selling 828 shares during the quarter. Seven Eight Capital LP’s holdings in DexCom were worth $708,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. CX Institutional acquired a new stake in shares of DexCom during the fourth quarter worth about $286,000. Bank of New Hampshire acquired a new stake in shares of DexCom during the first quarter worth about $1,508,000. abrdn plc lifted its holdings in shares of DexCom by 21.1% during the fourth quarter. abrdn plc now owns 380,535 shares of the medical device company’s stock worth $47,221,000 after purchasing an additional 66,348 shares during the period. Cerity Partners LLC lifted its holdings in shares of DexCom by 5,791.0% during the fourth quarter. Cerity Partners LLC now owns 463,973 shares of the medical device company’s stock worth $57,574,000 after purchasing an additional 456,097 shares during the period. Finally, Eagle Asset Management Inc. lifted its holdings in shares of DexCom by 21.5% during the fourth quarter. Eagle Asset Management Inc. now owns 1,756,216 shares of the medical device company’s stock worth $217,929,000 after purchasing an additional 310,728 shares during the period. Institutional investors own 97.75% of the company’s stock.

DexCom Price Performance

Shares of DXCM stock traded up $0.48 during trading hours on Tuesday, hitting $112.13. 2,370,353 shares of the company’s stock were exchanged, compared to its average volume of 2,856,005. The company has a quick ratio of 2.53, a current ratio of 2.90 and a debt-to-equity ratio of 1.08. The firm has a market cap of $44.59 billion, a P/E ratio of 72.03, a P/E/G ratio of 2.73 and a beta of 1.16. The firm has a 50 day moving average of $117.74 and a two-hundred day moving average of $124.57. DexCom, Inc. has a fifty-two week low of $74.75 and a fifty-two week high of $142.00.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Thursday, April 25th. The medical device company reported $0.32 EPS for the quarter, beating the consensus estimate of $0.27 by $0.05. DexCom had a return on equity of 31.01% and a net margin of 16.82%. The firm had revenue of $921.00 million during the quarter, compared to the consensus estimate of $911.20 million. Sell-side analysts forecast that DexCom, Inc. will post 1.78 EPS for the current year.

Analysts Set New Price Targets

A number of research firms recently commented on DXCM. UBS Group lifted their target price on DexCom from $153.00 to $163.00 and gave the stock a “buy” rating in a report on Wednesday, April 10th. StockNews.com cut DexCom from a “buy” rating to a “hold” rating in a research report on Monday, June 10th. Redburn Atlantic assumed coverage on DexCom in a research report on Thursday, May 30th. They set a “neutral” rating and a $130.00 price target for the company. Citigroup lifted their price target on DexCom from $148.00 to $161.00 and gave the company a “buy” rating in a research report on Wednesday, April 3rd. Finally, Raymond James lifted their price target on DexCom from $151.00 to $160.00 and gave the company a “strong-buy” rating in a research report on Friday, April 26th. Four equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $139.33.

Insider Activity at DexCom

In related news, EVP Michael Jon Brown sold 652 shares of the stock in a transaction on Friday, May 31st. The stock was sold at an average price of $119.24, for a total value of $77,744.48. Following the completion of the transaction, the executive vice president now directly owns 67,560 shares of the company’s stock, valued at approximately $8,055,854.40. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In related news, Director Bridgette P. Heller sold 1,000 shares of the stock in a transaction on Friday, June 14th. The stock was sold at an average price of $113.55, for a total value of $113,550.00. Following the completion of the transaction, the director now directly owns 25,349 shares of the company’s stock, valued at approximately $2,878,378.95. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Michael Jon Brown sold 652 shares of the company’s stock in a transaction on Friday, May 31st. The shares were sold at an average price of $119.24, for a total value of $77,744.48. Following the completion of the sale, the executive vice president now owns 67,560 shares of the company’s stock, valued at $8,055,854.40. The disclosure for this sale can be found here. In the last ninety days, insiders sold 4,112 shares of company stock valued at $480,861. 0.30% of the stock is owned by insiders.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.